Brief: Olema Oncology Announces New Clinical Trial Agreement With Pfizer To Combine Palazestrant With Atirmociclib In Er+/Her2- Metastatic Breast Cancer
02/09/2025 13:28
Olema Pharmaceuticals Inc OLMA.O: OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL AGREEMENT WITH PFIZER TO COMBINE PALAZESTRANT WITH ATIRMOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER OLEMA- UNDER AGREEMENT PFIZER TO SUPPLY ATIRMOCICLIB, OLEMA TO LEAD STUDY Source text: ID:nGNX4B0C9r Further company coverage: OLMA.O
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary